Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 0.80 |
| ▸ | CNR1 | P21554 | 11/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3687439 | 0.89 | CNR2 (1.00) | CNR2CNR1ALDH1A1HPGD | |
| SCHEMBL16404213 | 0.80 | CNR2 (1.00) | CNR2CNR1ALDH1A1HPGD | |
| SCHEMBL16404220 | 0.78 | CNR2 (1.00) | CNR2CNR1ALDH1A1HPGD | |
| SCHEMBL16404244 | 0.78 | CNR2 (1.00) | CNR2CNR1ALDH1A1HPGD | |
| SCHEMBL16404250 | 0.78 | CNR2 (0.79) | CNR2CNR1ALDH1A1HPGD | |
| SCHEMBL16404229 | 0.78 | CNR2 (0.79) | CNR2CNR1 | |
| SCHEMBL16404236 | 0.78 | CNR2 (1.00) | CNR2CNR1ALDH1A1HPGD | |
| SCHEMBL16404193 | 0.77 | CNR2 (1.00) | CNR2CNR1ALDH1A1HPGD | |
| SCHEMBL16404243 | 0.77 | CNR2 (1.00) | CNR2CNR1ALDH1A1HPGD | |
| SCHEMBL16404217 | 0.76 | CNR2 (0.75) | CNR2CNR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937184-B2 | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators | ABBVIE B.V. (NL) | 2015-01-20 | — | — | US | disclosed |
| US-8937184-B2 | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators | ABBVIE B.V. (NL) | 2015-01-20 | — | — | US | disclosed |
| US-8937184-B2 | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators | ABBVIE B.V. (NL) | 2015-01-20 | — | — | US | disclosed |
| EP-1874734-A1 | 1H-IMIDIAZOLE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS | Solvay Pharmaceuticals B.V. (NL) | 2008-01-09 | — | — | EP | disclosed |
| US-20060194779-A1 | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators | ABBVIE B.V. (NL) | 2006-08-31 | — | — | US | disclosed |
| WO-2006087355-A1 | 1H-IMIDIAZOLE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194779-A1 | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators | CNR1, CNR2, HRH4 | CNR2 2/4885CNR1 1/4885ALDH1A1 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.